December 2, 2025 08:46 AM EST Updated 01:17 PM StartupsR&D He­licore stops work on clin­i­cal GIP an­tag­o­nist af­ter Phase 1 re­sults, will fo­cus on oth­er drugs in pipeline Kyle LaHucik Biotech Correspondent He­licore Bio­phar­ma has end­ed a clin­i­cal tri­al for its lead as­set less than 12 months af­ter emerg­ing from stealth, and plans to shift fo­cus to … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER ENDPOINTS CAREERS Analyst – Life Sciences Strategy & Intelligence Sedulo Group Remote VIEW JOB OFFER post your job now